Goblet cell proliferation

Goblet cell proliferation is a biological process involving the expansion and differentiation of specialized epithelial cells that secrete protective mucins (primarily MUC5AC and MUC5B) in the respiratory and gastrointestinal tracts. While essential for maintaining the mucosal barrier, pathological proliferation—often termed goblet cell hyperplasia or mucus cell metaplasia—is a central feature of chronic airway diseases such as asthma and chronic obstructive pulmonary disease (COPD), where it leads to airway obstruction and impaired lung function [1, 2]. The process is tightly regulated by signaling pathways like Notch, which inhibits goblet cell differentiation, and Th2-associated cytokines such as IL-13, which drive it [2, 3]. In contrast, a deficiency in goblet cell proliferation is associated with inflammatory bowel diseases like ulcerative colitis, which compromises the intestinal lining [4]. Therapeutic interventions generally target molecular drivers of this process, such as IL-13 receptors or the master regulator transcription factor SPDEF, to normalize mucus production and improve patient outcomes [3, 5]. References: [1] Milano, J. et al. (2004). Modulation of Notch signaling regulates the differentiation of the intestinal epithelium. PMID: 15372042. [2] Wills-Karp, M. et al. (1998). Interleukin-13: central mediator of allergic asthma. PMID: 9851928. [3] Park, K. S. et al. (2007). Transcription factor SPDEF facilitates goblet cell differentiation and mucus hyperproduction. PMID: 17761889. [4] Gersemann, M. et al. (2009). Goblet cell differentiation and antibacterial effector mechanisms in inflammatory bowel disease. PMID: 19133817. [5] Corren, J. et al. (2011). Lebrikizumab treatment in adults with asthma. PMID: 21812663.

Other names

Goblet cell hyperplasiaMucus cell metaplasiaGoblet cell differentiationMucous metaplasia

Modulation of goblet cell proliferation occurs through the antagonism of Type 2 cytokines (IL-4/IL-13 signaling), inhibition of transcription factors like SPDEF, or manipulation of the Notch signaling pathway to prevent or promote secretory cell fate determination.